

Anaplastic Thyroid Cancer Drugs - Global Market Outlook (2017-2026)

<https://marketpublishers.com/r/A9686654934EN.html>

Date: June 2019

Pages: 164

Price: US\$ 4,150.00 (Single User License)

ID: A9686654934EN

Abstracts

According to Statistics MRC, the Global Anaplastic Thyroid Cancer Drugs market is accounted for \$ 139.56 million in 2017 and is expected to reach \$ 231.81 million by 2026 growing at a CAGR of 5.8% during the forecast period. Some of the key factors such as the existence of recompense policy for chemotherapy will include a useful blow which is propelling the growth of the market. However, the charge of this therapeutics is exceptionally high which is hampering the growth of the market.

Anaplastic Thyroid Cancer is the mainly exceptional thyroid cancer, in the main lethal thyroid cancer, and the main complex thyroid cancer to do surgery upon. The accurate operation depends upon the anaplastic thyroid cancer scope of the attack and is merely even measured suitable while there is extremely no proof that there is any remote spread of the infection. The entire anaplastic thyroid cancer is isolated from the neck in the early surgery. imperfect surgery is not correctable.

Based on the treatments available, Chemotherapy is universal treatment, which means that the medicine enters the blood torrent and travels all over the body to arrive at and demolish cancer cells. The Chemotherapy uses anti-cancer drugs to be injected into a layer or engaged by mouth. It is frequently joint with exterior beam radiation therapy for anaplastic thyroid cancer and is occasionally used for other higher cancers that no longer react to other treatments.

By Geography, North America was the maximum returns provider to the global anaplastic thyroid cancer drugs market. It will retain its top place during the forecast period. Anaplastic thyroid cancer is ordinary with adult citizens. Thus, the growing aged population in the region is most important to market growth. Furthermore, the rising quantity of awareness programs, being conducted by vendors and healthcare

organizations, are also bolstering the growth of the anaplastic thyroid cancer drugs market in North America.

Some of the key players profiled in the Anaplastic Thyroid Cancer Drugs Market include Pfizer Inc., Daiichi Sankyo Company, Limited, Trophogen, Inc., Plexxikon Inc., Novartis Ag, Millennium Pharmaceuticals Inc, Immune Pharmaceuticals Inc., and Genelux Corporation.

Types Covered:

Crolibulin

Efatutazone

GLONC-2

CLM-94

Other Types

Products Covered:

Sorafenib (phase 2)

Paclitaxel and Pazopanib HCl (phase 2)

MLN0128 (phase 2)

Lapatinib Ditosylate and Dabrafenib (phase 1)

Everolimus (phase 2)

CS7017 (phase 1)

Crolibulin (phase 1)

Cabozantinib (phase 2)

CA4P (phase 2)

Bevacizumab (phase 2)

Other Products

Treatments Covered:

Surgical Treatments

Radiation Therapy

Novel Therapy

Cryosurgery

Chemotherapy

Methods Covered:

Oral

Injection

Applications Covered:

Clinic

Hospital

Other Applications

Regions Covered:

North America

US

Canada

Mexico

Europe

Germany

UK

Italy

France

Spain

Rest of Europe

Asia Pacific

Japan

China

India

Australia

New Zealand

South Korea

Rest of Asia Pacific

South America

Argentina

Brazil

Chile

Rest of South America

Middle East & Africa

Saudi Arabia

UAE

Qatar

South Africa

Rest of Middle East & Africa

What our report offers:

Market share assessments for the regional and country level segments

Market share analysis of the top industry players

Strategic recommendations for the new entrants

Market forecasts for a minimum of 9 years of all the mentioned segments, sub-segments, and the regional markets

Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)

Strategic recommendations in key business segments based on the market estimations

Competitive landscaping mapping the key common trends

Company profiling with detailed strategies, financials, and recent developments

Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling

Comprehensive profiling of additional market players (up to 3)

SWOT Analysis of key players (up to 3)

Regional Segmentation

Market estimations, Forecasts and CAGR of any prominent country as per the clients interest (Note: Depends of feasibility check)

Competitive Benchmarking

Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Contents

1 EXECUTIVE SUMMARY

2 PREFACE

- 2.1 Abstract
- 2.2 Stake Holders
- 2.3 Research Scope
- 2.4 Research Methodology
 - 2.4.1 Data Mining
 - 2.4.2 Data Analysis
 - 2.4.3 Data Validation
 - 2.4.4 Research Approach
- 2.5 Research Sources
 - 2.5.1 Primary Research Sources
 - 2.5.2 Secondary Research Sources
 - 2.5.3 Assumptions

3 MARKET TREND ANALYSIS

- 3.1 Introduction
- 3.2 Drivers
- 3.3 Restraints
- 3.4 Opportunities
- 3.5 Threats
- 3.6 Product Analysis
- 3.7 Application Analysis
- 3.8 Emerging Markets
- 3.9 Futuristic Market Scenario

4 PORTERS FIVE FORCE ANALYSIS

- 4.1 Bargaining power of suppliers
- 4.2 Bargaining power of buyers
- 4.3 Threat of substitutes
- 4.4 Threat of new entrants
- 4.5 Competitive rivalry

5 GLOBAL ANAPLASTIC THYROID CANCER DRUGS MARKET, BY TYPE

- 5.1 Introduction
- 5.2 Crolibulin
- 5.3 Efatutazone
- 5.4 GLONC-2
- 5.5 CLM-94
- 5.6 Other Types

6 GLOBAL ANAPLASTIC THYROID CANCER DRUGS MARKET, BY PRODUCT

- 6.1 Introduction
- 6.2 Sorafenib (phase 2)
- 6.3 Paclitaxel and Pazopanib HCl (phase 2)
- 6.4 MLN0128 (phase 2)
- 6.5 Lapatinib Ditosylate and Dabrafenib (phase 1)
- 6.6 Everolimus (phase 2)
- 6.7 CS7017 (phase 1)
- 6.8 Crolibulin (phase 1)
- 6.9 Cabozantinib (phase 2)
- 6.10 CA4P (phase 2)
- 6.11 Bevacizumab (phase 2)
- 6.12 Other Products

7 GLOBAL ANAPLASTIC THYROID CANCER DRUGS MARKET, BY TREATMENTS

- 7.1 Introduction
- 7.2 Surgical Treatments
- 7.3 Radiation Therapy
- 7.4 Novel Therapy
- 7.5 Cryosurgery
- 7.6 Chemotherapy

8 GLOBAL ANAPLASTIC THYROID CANCER DRUGS MARKET, BY METHOD

- 8.1 Introduction
- 8.2 Oral
- 8.3 Injection

9 GLOBAL ANAPLASTIC THYROID CANCER DRUGS MARKET, BY APPLICATION

- 9.1 Introduction
- 9.2 Clinic
- 9.3 Hospital
- 9.4 Other Applications

10 GLOBAL ANAPLASTIC THYROID CANCER DRUGS MARKET, BY GEOGRAPHY

- 10.1 Introduction
- 10.2 North America
 - 10.2.1 US
 - 10.2.2 Canada
 - 10.2.3 Mexico
- 10.3 Europe
 - 10.3.1 Germany
 - 10.3.2 UK
 - 10.3.3 Italy
 - 10.3.4 France
 - 10.3.5 Spain
 - 10.3.6 Rest of Europe
- 10.4 Asia Pacific
 - 10.4.1 Japan
 - 10.4.2 China
 - 10.4.3 India
 - 10.4.4 Australia
 - 10.4.5 New Zealand
 - 10.4.6 South Korea
 - 10.4.6 Rest of Asia Pacific
- 10.5 South America
 - 10.5.1 Argentina
 - 10.5.2 Brazil
 - 10.5.3 Chile
 - 10.5.4 Rest of South America
- 10.6 Middle East & Africa
 - 10.6.1 Saudi Arabia
 - 10.6.2 UAE
 - 10.6.3 Qatar
 - 10.6.4 South Africa

10.6.5 Rest of Middle East & Africa

11 KEY DEVELOPMENTS

11.1 Agreements, Partnerships, Collaborations and Joint Ventures

11.2 Acquisitions & Mergers

11.3 New Product Launch

11.4 Expansions

11.5 Other Key Strategies

12 COMPANY PROFILING

12.1 Pfizer Inc.

12.2 Daiichi Sankyo Company, Limited

12.3 Trophogen, Inc.

12.4 Plexxikon Inc.

12.5 Novartis AG

12.6 Millennium Pharmaceuticals Inc

12.7 Immune Pharmaceuticals Inc.

12.8 Genelux Corporation

List Of Tables

LIST OF TABLES

- Table 1 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Region (2016-2026) (US \$MN)
- Table 2 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Type (2016-2026) (US \$MN)
- Table 3 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Crolibulin (2016-2026) (US \$MN)
- Table 4 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Efatutazone (2016-2026) (US \$MN)
- Table 5 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By GLONC-2 (2016-2026) (US \$MN)
- Table 6 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By CLM-94 (2016-2026) (US \$MN)
- Table 7 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Other Types (2016-2026) (US \$MN)
- Table 8 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Product (2016-2026) (US \$MN)
- Table 9 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Sorafenib (phase 2) (2016-2026) (US \$MN)
- Table 10 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Paclitaxel and Pazopanib HCl (phase 2) (2016-2026) (US \$MN)
- Table 11 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By MLN0128 (phase 2) (2016-2026) (US \$MN)
- Table 12 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Lapatinib Ditosylate and Dabrafenib (phase 1) (2016-2026) (US \$MN)
- Table 13 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Everolimus (phase 2) (2016-2026) (US \$MN)
- Table 14 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By CS7017 (phase 1) (2016-2026) (US \$MN)
- Table 15 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Crolibulin (phase 1) (2016-2026) (US \$MN)
- Table 16 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Cabozantinib (phase 2) (2016-2026) (US \$MN)
- Table 17 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By CA4P (phase 2) (2016-2026) (US \$MN)
- Table 18 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Bevacizumab

(phase 2) (2016-2026) (US \$MN)

Table 19 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Other Products (2016-2026) (US \$MN)

Table 20 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Treatments (2016-2026) (US \$MN)

Table 21 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Surgical Treatments (2016-2026) (US \$MN)

Table 22 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Radiation Therapy (2016-2026) (US \$MN)

Table 23 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Novel Therapy (2016-2026) (US \$MN)

Table 24 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Cryosurgery (2016-2026) (US \$MN)

Table 25 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Chemotherapy (2016-2026) (US \$MN)

Table 26 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Method (2016-2026) (US \$MN)

Table 27 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Oral (2016-2026) (US \$MN)

Table 28 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Injection (2016-2026) (US \$MN)

Table 29 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Application (2016-2026) (US \$MN)

Table 30 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Clinic (2016-2026) (US \$MN)

Table 31 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Hospital (2016-2026) (US \$MN)

Table 32 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Other Applications (2016-2026) (US \$MN)

NOTE: Tables for North America, Europe, Asia Pacific, South America, and Middle East & Africa are represented in the same manner above.

I would like to order

Product name: Anaplastic Thyroid Cancer Drugs - Global Market Outlook (2017-2026)

Product link: <https://marketpublishers.com/r/A9686654934EN.html>

Price: US\$ 4,150.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A9686654934EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970